Participant flow

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer · Source last updated 2026-04-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.

   id

   FG000

   title

   150 mg Abemaciclib + Endocrine Therapy

2. description

   Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.

   id

   FG001

   title

   Endocrine Therapy

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         119

      2. group Id

         FG001

         num Subjects

         134

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         12

      2. group Id

         FG001

         num Subjects

         13

      type

      Lost to Follow-up

   3. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Missing disposition data

   4. reasons

      1. group Id

         FG000

         num Subjects

         2027

      2. group Id

         FG001

         num Subjects

         2074

      type

      On study treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         2808

      2. group Id

         FG001

         num Subjects

         2829

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         2791

      2. group Id

         FG001

         num Subjects

         2800

      type

      Received at Least One Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         650

      2. group Id

         FG001

         num Subjects

         607

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         2158

      2. group Id

         FG001

         num Subjects

         2222

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Completers included participants who had recurrence disease, death due to any cause, and participants off treatment but on study follow-up.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice